Visceral Fat & Tesamorelin Therapy

Visceral fat is different from the fat you can see or pinch. It sits deep inside your abdomen, wrapped around your organs — and it behaves more like an active gland than stored energy. Visceral fat releases inflammatory compounds including IL-6 and TNF-alpha that drive insulin resistance, making your body increasingly resistant to fat loss the longer it accumulates.

This is especially common during perimenopause. As estrogen declines, the body naturally shifts fat storage toward the abdomen — even in women who haven't changed their diet or exercise habits. The result is a frustrating cycle: more visceral fat drives more inflammation, and more inflammation makes losing that fat harder.

GLP-1 medications like semaglutide are highly effective for appetite control and improving insulin signaling — but they aren't designed to directly address visceral fat or the inflammatory cycle driving it. That's why some patients hit a plateau even while staying fully consistent with their medication, nutrition, and movement.

If the scale has stopped moving but you're doing everything right, the issue may not be compliance — it may be that the root cause hasn't been targeted yet.